- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04977882
Abdominal Drainage, Postoperative Antibiotico-prophylaxis and CME With D3 Lyphadenectomy Effect on Gastrointestinal Function in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis for Right Colon Cancer
November 20, 2023 updated by: Giuseppe Sigismondo Sica, University of Rome Tor Vergata
Monocentric, two-level factorial, parallel-arm, pilot randomized clinical trial, conducted comparing patients undergoing laparoscopic right hemicolectomy with ICA for right colon cancer in a single unit of a teaching hospital: Minimally Invasive Surgery Unit, Department of Surgical Sciences, Policlinico Tor Vergata, Rome, Italy.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rome, Italy, 00133
- University of Rome Tor Vergata
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Right colon cancer
- Intracorporeal anastomosis
- Laparoscopic surgery
- Elective surgery
- informed consent signed
Exclusion Criteria:
- below 18 years old
- IBD
- ASA IV
- T4b
- Metastatic disease
- Preoperative steroids
- Conversion to open surgery
- Emergency surgery
- concomitant major operation
- preoperative infective status
- benign disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Abdominal drainage
19 Fr abdominal drainage placed intraoperatevely in right paracolic gutter
|
19 Fr abdominal drainage placed intraoperatively in right colic gutter
the dissection starts over the landmark given by SMV.
The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue.
Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels.
The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH.
No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas.
At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure.
The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia.
The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV).
The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon.
The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
|
|
Experimental: Postoperative antibiotico-prophylaxis
postoperative antibiotico-prophylaxis with Ceftriaxone 2gr and Metronidazole 1.5gr
|
Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively
the dissection starts over the landmark given by SMV.
The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue.
Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels.
The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH.
No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas.
At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure.
The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia.
The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV).
The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon.
The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
|
|
Sham Comparator: Control group
No drainage nor postoperative antibiotico-prophylaxis
|
the dissection starts over the landmark given by SMV.
The SMV is freed anteriorly and on its right-hand side from all the lympho-adipose tissue.
Once the SMV is fully exposed, the IC vessels are dissected and divided at the junction with the efferent vessels.
The dissection moves upward along the same dissection line to identify the right colic vein and the GCTH.
No medial to later dissection is carried out until the SMV is completely exposed before reaching the uncinate process of the pancreas.
At this point the veins to the right colon are divided but gastroepiploic vein and artery are preserved unless the tumor is located at the hepatic flexure.
The divided mesentery is lifted and tilted to the right, and the medial-to-later dissection starts following the embryological plane over Fredet's fascia.
The mesocolon is divided on the right side of the middle colic artery and the right branches of the middle colic vessels are divided.
A medial-to-lateral surgical dissection and high tie of the ileocolic vessels (IC) is undertaken without dissecting the anterior surface of the superior mesenteric vein (SMV).
The gastro-colic trunk of Henle (GCTH) is not isolated and the right colic vein (when present) and the right branches of the middle colic vessels are taken more peripherical, during the division of the transverse mesocolon.
The right gastroepiploic vessels are not dissected, nor divided, unless in proximity of the tumor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tolerance to solid diet
Time Frame: 30 days postoperatively
|
time to light diet tolerance
|
30 days postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
C-Reactive Proteine
Time Frame: 30 days postoperatively
|
measured mg/L in I and III POD
|
30 days postoperatively
|
|
White blood cell
Time Frame: 30 days postoperatively
|
measured thousands/mL in I and III POD
|
30 days postoperatively
|
|
Procalcitonine
Time Frame: 30 days postoperatively
|
measured ng/ml in III and V POD
|
30 days postoperatively
|
|
Days of hospitalization
Time Frame: 90 days postoperatively
|
number of days of hospitalization
|
90 days postoperatively
|
|
Readmission rate
Time Frame: 90 days postoperatively
|
rate of hospital readmission
|
90 days postoperatively
|
|
Mortality rate
Time Frame: 90 days postoperatively
|
postoperative mortality
|
90 days postoperatively
|
|
Surgical site infection rate
Time Frame: 30 days postoperatively
|
postoperative wound infection
|
30 days postoperatively
|
|
Anastomotic leak rate
Time Frame: 30 days postoperatively
|
postoperative Ileocolic anastomotic leakage
|
30 days postoperatively
|
|
Tolerance to liquid diet
Time Frame: 30 days postoperatively
|
time to clear fluid tolerance
|
30 days postoperatively
|
|
Time to first flatus
Time Frame: 30 days postoperatively
|
Time to first flatus postoperatively
|
30 days postoperatively
|
|
Time to first evacuation
Time Frame: 30 days postoperatively
|
Time to first evacuation postoperatively
|
30 days postoperatively
|
|
need of abdomen CTscan rate
Time Frame: 30 days postoperatively
|
need of abdomen CTscan
|
30 days postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Actual)
August 1, 2022
Study Completion (Actual)
August 1, 2023
Study Registration Dates
First Submitted
July 15, 2021
First Submitted That Met QC Criteria
July 25, 2021
First Posted (Actual)
July 27, 2021
Study Record Updates
Last Update Posted (Estimated)
November 22, 2023
Last Update Submitted That Met QC Criteria
November 20, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Registro sperimentazioni XX.21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
Chaoxi ZhouRecruitingProximal Transverse Colon Cancer | Ascending Colon CancerChina
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineSuspendedStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Chang Gung Memorial HospitalCompletedColon Cancer | Cancer Recurrence | Colon Adenocarcinoma | Colon Cancer Stage II | Colon Cancer Stage I | Survival Analysis | Colon Cancer Stage IIITaiwan
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
Clinical Trials on abdominal drainage
-
Ruijin HospitalRenJi HospitalUnknown
-
Centre Hospitalier Universitaire VaudoisUnknownSurgery | Appendicitis | Diverticulitis | PancreatitisSwitzerland
-
FluidAI MedicalHamilton Health Sciences CorporationRecruiting
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingDrainage | Liver Transplant; Complications
-
Chaoyang Hospital of China Medical UniversityCompletedPostoperative Gastrointestinal Dysfunction (POGD)China
-
University Clinical Center TuzlaUnknown
-
Duke UniversityCareFusionCompletedPleural Effusion, MalignantUnited States
-
University Health Network, TorontoTerminated
-
Prof A Gruca Teaching HospitalCompletedBleeding | Hip Osteoarthritis
-
Peking University People's HospitalUnknownKnee Osteoarthritis